3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombosis
1
Thrombophilia
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pulmonary Embolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Multiple Myeloma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Interventions
Cyclophosphamide
444
Rituximab
401
Etoposide
224
Vincristine
215
Doxorubicin
201
Filgrastim
200
Prednisone
176
Cytarabine
159
Radiotherapy
152
fludarabine phosphate
147
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
129
Melphalan
127
fludarabine
115
Busulfan
99
Dexamethasone
93
Tacrolimus
75
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
71
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
62
Cyclosporine
62
Bendamustine Hydrochloride
62
Lenalidomide
60
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma
×
enoxaparin sodium
×
Clear all
NCT07270263
2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA
Recruiting
100 enrolled